irganox 1010 has been researched along with Psoriasis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbiser, J; Banga, AK; Coulon, R; Gujjar, M | 1 |
1 other study(ies) available for irganox 1010 and Psoriasis
| Article | Year |
|---|---|
Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.
Topics: Administration, Cutaneous; Cell Survival; Chemistry, Pharmaceutical; Dermatologic Agents; Emulsions; Humans; Interleukin-6; Phenylpropionates; Propylene Glycols; Proteasome Inhibitors; Psoriasis; Skin; Skin Absorption; Solubility | 2016 |